Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,742 | 250 | 97.8% |
| Education | $152.51 | 6 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,480 | 59 | $0 (2023) |
| Daiichi Sankyo Inc. | $1,113 | 68 | $0 (2019) |
| GlaxoSmithKline, LLC. | $932.00 | 33 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $867.51 | 15 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $525.08 | 14 | $0 (2021) |
| ABBVIE INC. | $499.66 | 13 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $319.92 | 15 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $266.22 | 4 | $0 (2022) |
| Genentech USA, Inc. | $169.34 | 3 | $0 (2020) |
| ITI, Inc. | $155.01 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $139.65 | 6 | GlaxoSmithKline, LLC. ($62.61) |
| 2022 | $859.63 | 32 | ABBVIE INC. ($357.07) |
| 2021 | $537.92 | 19 | GlaxoSmithKline, LLC. ($242.41) |
| 2020 | $299.75 | 11 | Genentech USA, Inc. ($149.66) |
| 2019 | $966.32 | 30 | Boehringer Ingelheim Pharmaceuticals, Inc. ($261.16) |
| 2018 | $1,597 | 72 | Daiichi Sankyo Inc. ($493.50) |
| 2017 | $2,495 | 86 | AstraZeneca Pharmaceuticals LP ($547.82) |
All Payment Transactions
256 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/26/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/31/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/10/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $31.96 | General |
| Category: RESPIRATORY | ||||||
| 03/23/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: RESPIRATORY | ||||||
| 01/19/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/12/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Respiratory | ||||||
| 12/22/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $5.95 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2022 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: INSOMNIA | ||||||
| 12/07/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/13/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Respiratory | ||||||
| 10/04/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: NEUROSCIENCE | ||||||
| 09/22/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: Respiratory | ||||||
| 09/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: NEUROSCIENCE | ||||||
| 08/18/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: RESPIRATORY | ||||||
| 08/15/2022 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Central Nervous System | ||||||
| 08/01/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: Respiratory | ||||||
| 07/28/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: NEUROSCIENCE | ||||||
| 07/25/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: PSYCHIATRY | ||||||
| 07/18/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Respiratory | ||||||
| 07/13/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $8.53 | General |
| Category: NEUROSCIENCE | ||||||
| 07/06/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: PSYCHIATRY | ||||||
| 06/08/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: NEUROSCIENCE | ||||||
| 05/25/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: PSYCHIATRY | ||||||
| 05/19/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 377 | 903 | $127,501 | $59,465 |
| 2022 | 8 | 369 | 871 | $120,135 | $58,999 |
| 2021 | 7 | 405 | 987 | $129,675 | $61,473 |
| 2020 | 7 | 495 | 1,165 | $174,283 | $80,115 |
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 414 | $64,170 | $29,017 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 178 | $30,616 | $19,496 | 63.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 50 | 97 | $9,603 | $4,533 | 47.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 60 | 91 | $14,196 | $2,936 | 20.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 11 | 11 | $1,650 | $1,617 | 98.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 57 | 84 | $6,384 | $1,002 | 15.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 17 | 17 | $442.00 | $433.16 | 98.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 11 | 11 | $440.00 | $431.20 | 98.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 114 | 475 | $73,625 | $37,326 | 50.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 68 | 140 | $13,860 | $7,310 | 52.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 40 | 62 | $10,664 | $6,857 | 64.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 57 | 86 | $13,416 | $3,013 | 22.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 20 | 20 | $3,000 | $2,957 | 98.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 44 | 62 | $4,712 | $817.18 | 17.3% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2022 | 13 | 13 | $520.00 | $388.01 | 74.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 13 | 13 | $338.00 | $331.76 | 98.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 109 | 473 | $73,315 | $38,985 | 53.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 96 | 240 | $23,760 | $9,453 | 39.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 25 | 35 | $6,020 | $4,238 | 70.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 24 | 24 | $3,600 | $3,600 | 100.0% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 60 | 93 | $14,508 | $3,550 | 24.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 75 | 106 | $8,056 | $1,320 | 16.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 16 | 16 | $416.00 | $326.08 | 78.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 129 | 538 | $92,536 | $48,392 | 52.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 120 | 287 | $44,485 | $18,345 | 41.2% |
About Dr. John Jacoby, MD
Dr. John Jacoby, MD is a General Practice healthcare provider based in New Rochelle, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790853778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Jacoby, MD has received a total of $6,895 in payments from pharmaceutical and medical device companies, with $139.65 received in 2023. These payments were reported across 256 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($6,742).
As a Medicare-enrolled provider, Jacoby has provided services to 1,646 Medicare beneficiaries, totaling 3,926 services with total Medicare billing of $260,052. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Practice Information
- Specialty General Practice
- Location New Rochelle, NY
- Active Since 11/30/2006
- Last Updated 07/08/2007
- Taxonomy Code 208D00000X
- Entity Type Individual
- NPI Number 1790853778
Products in Payments
- FARXIGA (Drug) $624.75
- Morphabond ER (Drug) $593.87
- Movantik (Drug) $457.15
- TRELEGY ELLIPTA (Drug) $454.06
- BEVESPI AEROSPHERE (Drug) $372.63
- INVOKANA (Drug) $300.62
- SPIRIVA RESPIMAT (Drug) $269.92
- VRAYLAR (Drug) $239.32
- XARELTO (Drug) $224.46
- ANORO (Drug) $213.28
- BELSOMRA (Drug) $208.17
- Xofluza (Drug) $169.34
- ANORO ELLIPTA (Drug) $167.11
- CAPLYTA (Drug) $155.01
- BREZTRI (Drug) $145.00
- SYMBICORT (Drug) $139.43
- AUSTEDO (Drug) $137.04
- AJOVY (Drug) $129.18
- Humira (Biological) $117.59
- QULIPTA (Drug) $108.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in New Rochelle
Dr. Ralph Essien, M.d, M.D
General Practice — Payments: $5,011
Dr. John Ambrose, Dds, DDS
General Practice — Payments: $2,114
Dr. Martin Rube, D.d.s, D.D.S
General Practice — Payments: $2,082
Dr. Nida Soriano-Bartolome, D.d.s, D.D.S
General Practice — Payments: $1,805
Dr. John Como, Dds, DDS
General Practice — Payments: $1,586
Dr. Dennis Chan, Dds, DDS
General Practice — Payments: $1,305